Joshua Blight
CEO/Co-Founder
Baseimmune
Baseimmune utilizes a proprietary AI platform to design mutation-resistant vaccines by modeling pathogen evolution and immune responses. The company addresses the challenge of vaccine efficacy against emerging and complex pathogens that traditional methods fail to target.
- Artificial Intelligence
- Biotechnology
Updated 17 days ago
Funding
Raised to date
$16.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$12.2M across 2 disclosed rounds
IC+3$11.3M · Series A
Announced Feb 2024 · from article date
Disclosed cumulative: $12.2M
2/2
Reported total $16.3M
Incomplete round history. $4.1M of the $16.3M reported total isn’t matched to a known round.
RoundDateAmountValuationInvestors
Founders
Product
Problem
Traditional vaccine development struggles to keep pace with rapidly evolving pathogens, leading to reduced efficacy against emerging variants and complex diseases. Current methods often fail to predict and target future mutations, resulting in vaccines that offer limited or short-lived protection. This is particularly challenging for pathogens like coronaviruses, malaria, and African swine fever, which exhibit high mutation rates and strain diversity.
Solution
Baseimmune is developing mutation-resistant vaccines using a proprietary AI-driven platform that models pathogen evolution and immune responses. The platform integrates genomic, proteomic, epidemiological, and immunological data to identify conserved and vulnerable regions across multiple strains and species. This enables the design of multi-target de novo antigens that maintain coverage even as pathogens mutate. The company's approach aims to create broader, longer-lasting vaccines that can address the challenges posed by emerging and complex pathogens, including human and veterinary diseases.
Target Audience
The primary target audience includes pharmaceutical companies, veterinary medicine developers, and global health organizations seeking to develop more effective and durable vaccines against rapidly evolving pathogens.
Features
- AI-driven platform for predicting pathogen evolution and immune responses
- Multi-target de novo antigen generation for broad coverage
- Vaccine candidates tested as mRNA/LNP or viral vectors
- Early-stage pipeline includes vaccines against pancoronaviruses, malaria, and African swine fever
- Models genomic, proteomic, epidemiological, and immunological data
- Laboratory validation of AI-generated vaccine candidates